Ryan Deschner

“If you're curious on what your current thinking is on how quickly orders associated with McKesson deal might develop over the next several quarters, how much overlap on call points with existing customers is there or do you think there will be, if you give us an idea of how payment terms compare between McKesson and…”

“Curious what your overall take is on the potential read-through from the BOLD study evaluating Otovixabat in patients with biliary atresia. And I have a follow-up question.”

“One, have your expectations for what a potential label might look like in MLM evolved since your pre-NDA meeting with FDA in terms of age cutoff or otherwise?”

“Just two questions, one on how firm depth the updated dosing strategy may be for the oral portion of the maintenance study, and if you'd expect a similar number of cohorts as you're running in the injectable maintenance portion.”

“You know, what's your strategy for identifying FOP patients in the U.S. and abroad and addressing the relatively high misdiagnosis rate for FOP?”